- Report
- June 2024
- 200 Pages
Global
From €6355EUR$6,360USD£5,273GBP
€7943EUR$7,950USD£6,592GBP
- Report
- June 2024
- 200 Pages
Global
From €6355EUR$6,360USD£5,273GBP
€7943EUR$7,950USD£6,592GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €999EUR$1,000USD£829GBP
€1249EUR$1,250USD£1,036GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €999EUR$1,000USD£829GBP
€1249EUR$1,250USD£1,036GBP
- Clinical Trials
- January 2024
- 90 Pages
Global
From €1199EUR$1,200USD£995GBP
€1499EUR$1,500USD£1,244GBP
- Report
- March 2024
- 200 Pages
Global
From €4147EUR$4,150USD£3,441GBP
- Report
- December 2024
- 144 Pages
Global
From €10986EUR$10,995USD£9,117GBP
- Report
- December 2024
- 50 Pages
Global
From €2648EUR$2,650USD£2,197GBP
- Report
- December 2024
- 50 Pages
Global
From €2648EUR$2,650USD£2,197GBP
- Report
- December 2024
- 50 Pages
Global
From €2648EUR$2,650USD£2,197GBP
- Report
- December 2024
- 50 Pages
Global
From €2648EUR$2,650USD£2,197GBP
- Report
- December 2024
- 50 Pages
Global
From €2648EUR$2,650USD£2,197GBP
- Report
- September 2018
- 174 Pages
Global
From €1374EUR$1,375USD£1,140GBP
€2748EUR$2,750USD£2,280GBP
- Report
- March 2019
- 39 Pages
Global
€9992EUR$10,000USD£8,292GBP
- Report
- March 2019
- 62 Pages
Global
€9992EUR$10,000USD£8,292GBP
- Report
- March 2019
- 33 Pages
Global
€9992EUR$10,000USD£8,292GBP
- Report
- April 2018
- 26 Pages
Global
From €9992EUR$10,000USD£8,292GBP
- Report
- March 2018
- 17 Pages
Global
From €9992EUR$10,000USD£8,292GBP
- Report
- March 2018
- 20 Pages
Global
From €9992EUR$10,000USD£8,292GBP
- Report
- October 2022
- 113 Pages
Global
From €4746EUR$4,750USD£3,938GBP
The Schizophrenia Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of medications used to treat schizophrenia. Schizophrenia is a mental disorder characterized by abnormal social behavior and failure to recognize what is real. Common symptoms include delusions, hallucinations, disorganized speech, and disorganized behavior.
The Schizophrenia Drugs market is composed of a variety of companies, including large pharmaceutical companies, small biotech firms, and generic drug manufacturers. These companies develop and market medications that are used to treat schizophrenia, such as antipsychotics, antidepressants, and mood stabilizers. Many of these medications are available in both generic and brand-name forms.
Some of the major companies in the Schizophrenia Drugs market include Johnson & Johnson, Pfizer, Eli Lilly, Novartis, and AstraZeneca. These companies have developed a range of medications to treat schizophrenia, including Abilify, Seroquel, Zyprexa, and Risperdal. Show Less Read more